Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (1044) 1044
Conference Proceeding (37) 37
Publication (28) 28
Patent (25) 25
Book Chapter (4) 4
Newspaper Article (4) 4
Book / eBook (3) 3
Book Review (1) 1
Data Set (1) 1
Dissertation (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (425) 425
male (328) 328
female (283) 283
index medicus (265) 265
middle aged (230) 230
aged (184) 184
adult (181) 181
oncology (156) 156
surgery (117) 117
cancer (88) 88
animals (86) 86
hematology (83) 83
medicine & public health (74) 74
retrospective studies (72) 72
prognosis (70) 70
colorectal cancer (68) 68
aged, 80 and over (65) 65
treatment outcome (63) 63
adolescent (59) 59
chemotherapy (59) 59
analysis (51) 51
care and treatment (50) 50
research (48) 48
transplantation (43) 43
metastasis (39) 39
neoplasm staging (38) 38
otorhinolaryngology (38) 38
disease-free survival (37) 37
follow-up studies (37) 37
tomography, x-ray computed (37) 37
young adult (37) 37
antineoplastic combined chemotherapy protocols - therapeutic use (36) 36
survival rate (35) 35
therapy (35) 35
child (34) 34
expression (33) 33
gastroenterology & hepatology (33) 33
risk factors (33) 33
survival (33) 33
apoptosis (32) 32
clinical neurology (32) 32
colorectal neoplasms - pathology (32) 32
patients (32) 32
magnetic resonance imaging (31) 31
tumors (30) 30
japan (29) 29
diagnosis (28) 28
mice (28) 28
rats (27) 27
guinea pigs (26) 26
biochemistry & molecular biology (25) 25
health aspects (25) 25
medicine (25) 25
mutation (25) 25
risk (25) 25
stem cells (25) 25
immunohistochemistry (24) 24
multiple myeloma (24) 24
physics, applied (24) 24
radiotherapy (23) 23
time factors (23) 23
chemistry (22) 22
japan - epidemiology (22) 22
pharmacology & pharmacy (22) 22
radiology, nuclear medicine & medical imaging (22) 22
colorectal neoplasms - surgery (21) 21
recurrence (21) 21
carcinoma (20) 20
colorectal-cancer (20) 20
combined modality therapy (20) 20
lymphatic metastasis (20) 20
medical research (20) 20
multivariate analysis (20) 20
case report (19) 19
cells (19) 19
child, preschool (19) 19
children (19) 19
prospective studies (19) 19
chemoradiotherapy (18) 18
colorectal neoplasms - mortality (18) 18
dna (18) 18
gastroenterology (18) 18
immunology (18) 18
internal medicine (18) 18
medicine, research & experimental (18) 18
metallurgy (18) 18
multidisciplinary sciences (18) 18
diseases (17) 17
kinetics (17) 17
original (17) 17
apoptosis - drug effects (16) 16
colon cancer (16) 16
dose-response relationship, drug (16) 16
flow cytometry (16) 16
hepatology (16) 16
neoplasm recurrence, local - pathology (16) 16
non-hodgkins-lymphoma (16) 16
oncology, experimental (16) 16
rectal cancer (16) 16
research article (16) 16
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Detection of MPLW515L/K mutations and determination of allele frequencies with a single-tube PCR assay
by Takei, Hiraku and Takei, Hiraku and Morishita, Soji and Morishita, Soji and Araki, Marito and Araki, Marito and Edahiro, Yoko and Edahiro, Yoko and Sunami, Yoshitaka and Sunami, Yoshitaka and Hironaka, Yumi and Hironaka, Yumi and Noda, Naohiro and Noda, Naohiro and Sekiguchi, Yuji and Sekiguchi, Yuji and Tsuneda, Satoshi and Tsuneda, Satoshi and Ohsaka, Akimichi and Ohsaka, Akimichi and Komatsu, Norio and Komatsu, Norio
PLoS ONE, ISSN 1932-6203, 2014, Volume 9, Issue 8, p. e104958
A gain-of-function mutation in the myeloproliferative leukemia virus (MPL) gene, which encodes the thrombopoietin receptor, has been identified in patients... 
MYELOFIBROSIS | MARROW FIBROSIS | NEOPLASMS | CHRONIC MYELOPROLIFERATIVE DISORDERS | MULTIDISCIPLINARY SCIENCES | MPL | JAK2 V617F MUTATION | ESSENTIAL THROMBOCYTHEMIA | BURDEN | PROBES | Receptors, Thrombopoietin - genetics | Gene Frequency - genetics | Mutation - genetics | Humans | Polymerase Chain Reaction | Gene mutations | Biomedical research | Myelofibrosis | Hematology | Leukemia | Viruses | Patients | Phase transitions | Neoplasms | Subgroups | Thrombopoietin | Medicine | Gene frequency | Alleles | Stem cells | Life sciences | Diagnostic systems | Mutation | Deoxyribonucleic acid--DNA | University graduates | Tumors | Deoxyribonucleic acid | DNA
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Detection of MPLW515L/K Mutations and Determination of Allele Frequencies with a Single-Tube PCR Assay
by Takei, H and Morishita, S and Araki, M and Edahiro, Y and Sunami, Y and Hironaka, Y
PLOS ONE, ISSN 1932-6203, 04/2015, Volume 10, Issue 4, p. e104958
MULTIDISCIPLINARY SCIENCES
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial
by Dimopoulos, Meletios A and Dimopoulos, Athanasios and Gay, Francesca and Schjesvold, Fredrik and Beksac, Meral and Hajek, Roman and Weisel, Katja Christina and Weisel, Katja and Goldschmidt, Hartmut and Maisnar, Vladimir and Moreau, Philippe and Min, Chang Ki and Pluta, Andrzej and Pluta, Agnieszka and Chng, Wee Joo and Chng, Wee-Joo and Kaiser, Martin and Zweegman, Sonja and Mateos, Maria-Victoria and Mateos, Maria Victoria and Spencer, Andrew and Iida, Shinsuke and Morgan, Gareth and Suryanarayan, Kaveri and Teng, Zhaoyang and Skacel, Tomas and Palumbo, Antonio and Dash, Ajeeta B and Gupta, Neeraj and Labotka, Richard and Rajkumar, S Vincent and Bar, Daniel and Basso, Alfredo and Fantl, Dorotea and He, Simon and Horvath, Neomi and Lee, Cindy and Lee, Jae Hoon and Rowlings, Phillip and Taylor, Kerry and Cochrane, Tara and Kwok, Fiona and Ramanathan, Sundreswran and Agis, Hermine and Zojer, Niklas and Kentos, Alain and Offner, Fritz and Van Droogenbroeck, Jan and Wu, Ka Lung and Maiolino, Angelo and Martinez, Gracia and Zanella, Karla and Capra, Marcelo and Araújo, Sérgio and Gregora, Evzen and Pour, Ludek and Scudla, Vlastimil and Spicka, Ivan and Abildgaard, Niels and Andersen, Niels and Jensen, Bo Amdi and Helleberg, Carsten and Plesner, Torben and Salomo, Morten and Svirskaite, Asta and Delarue, Richard and Blau, Igor and Schieferdecker, Aneta and Teleanu, Veronica and Munder, Markus and Röllig, Christoph and Salwender, Han-Juergen and Fuhrmann, Stephan and Duerig, Jan and Zeis, Matthias and Klein, Stefan and Reimer, Peter and Schmidt, Christian and Scheid, Christof and Mayer, Karin and Hoffmann, Martin and Sosada, Markus and Delimpasi, Sosana and Kyrtsonis, Mary-Christine and Anagnostopoulos, Achilleas and Nagy, Zsolt and Illés, Árpád and Egyed, Miklós and Borbényi, Zita and Mikala, Gabor and Dally, Najib and Horowitz, Netanel and Gutwein, Odit and Nemets, Anatoly and Vaxman, Iuliana and Shvetz, Olga and Trestman, Svetlana and Ruchlemer, Rosa and Nagler, Arnon and Tadmor, Tamar and ... and TOURMALINE-MM3 Study Grp and TOURMALINE-MM3 study group
The Lancet, ISSN 0140-6736, 01/2019, Volume 393, Issue 10168, pp. 253 - 264
Maintenance therapy following autologous stem cell transplantation (ASCT) can delay disease progression and prolong survival in patients with multiple myeloma.... 
DIAGNOSED MULTIPLE-MYELOMA | DEXAMETHASONE | HIGH-DOSE THERAPY | IMPROVES SURVIVAL | BORTEZOMIB | THALIDOMIDE | INDUCTION | LENALIDOMIDE MAINTENANCE | CHEMOTHERAPY | MEDICINE, GENERAL & INTERNAL | Therapy | Transplants & implants | Toxicity | Multiple myeloma | Medical services | Clinical trials | Stem cell transplantation | Transplantation | Peripheral neuropathy | Randomization | Motivation | Melphalan | Diagnosis | Safety | Drug dosages | Autografts | Cell survival | Hematology | Maintenance | Patients | Survival | Chemotherapy | Stem cells | Adults | Tourmaline | Pharmaceuticals | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Detection of MPLW515L/K Mutations and Determination of Allele Frequencies with a Single-Tube PCR Assay: e104958
by Takei, Hiraku and Morishita, Soji and Araki, Marito and Edahiro, Yoko and Sunami, Yoshitaka and Hironaka, Yumi and Noda, Naohiro and Sekiguchi, Yuji and Tsuneda, Satoshi and Ohsaka, Akimichi
PLoS ONE, 08/2014, Volume 9, Issue 8
A gain-of-function mutation in the myeloproliferative leukemia virus (MPL) gene, which encodes the thrombopoietin receptor, has been identified in patients... 
Journal Article
Details down arrow
5. Full Text Association of variations in HLA class II and other loci with susceptibility to EGFR-mutated lung adenocarcinoma
by Shiraishi, Kouya and Okada, Yukinori and Takahashi, Atsushi and Kamatani, Yoichiro and Momozawa, Yukihide and Ashikawa, Kyota and Kunitoh, Hideo and Matsumoto, Shingo and Takano, Atsushi and Shimizu, Kimihiro and Goto, Akiteru and Tsuta, Koji and Watanabe, Shun-Ichi and Ohe, Yuichiro and Watanabe, Yukio and Goto, Yasushi and Nokihara, Hiroshi and Furuta, Koh and Yoshida, Akihiko and Goto, Koichi and Hishida, Tomoyuki and Tsuboi, Masahiro and Tsuchihara, Katsuya and Miyagi, Yohei and Nakayama, Haruhiko and Yokose, Tomoyuki and Tanaka, Kazumi and Nagashima, Toshiteru and Ohtaki, Yoichi and Maeda, Daichi and Imai, Kazuhiro and Minamiya, Yoshihiro and Sakamoto, Hiromi and Saito, Akira and Shimada, Yoko and Sunami, Kuniko and Saito, Motonobu and Inazawa, Johji and Nakamura, Yusuke and Yoshida, Teruhiko and Yokota, Jun and Matsuda, Fumihiko and Matsuo, Keitaro and Daigo, Yataro and Kubo, Michiaki and Kohno, Takashi
Nature Communications, ISSN 2041-1723, 08/2016, Volume 7, Issue 1, p. 12451
Lung adenocarcinoma driven by somatic EGFR mutations is more prevalent in East Asians (30-50%) than in European/Americans (10-20%). Here we investigate genetic... 
VARIANTS | MULTIDISCIPLINARY SCIENCES | NEVER SMOKERS | RISK | JAPANESE | SMOKING | MUTATIONS | POLYMORPHISM | FUSIONS | CANCER | GENOME-WIDE ASSOCIATION | Lung Neoplasms - genetics | Genetic Predisposition to Disease | Genome-Wide Association Study | Reproducibility of Results | Adenocarcinoma of Lung | Humans | Risk Factors | ErbB Receptors - genetics | Genetic Loci | Forkhead Transcription Factors - genetics | Mutation - genetics | Polymorphism, Single Nucleotide - genetics | Adenocarcinoma - genetics | Histocompatibility Antigens Class II - genetics
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Clinical practice guidance for next‐generation sequencing in cancer diagnosis and treatment (Edition 1.0)
by Sunami, Kuniko and Takahashi, Hideaki and Tsuchihara, Katsuya and Takeda, Masayuki and Suzuki, Tatsuya and Naito, Yoichi and Sakai, Kazuko and Dosaka‐Akita, Hirotoshi and Ishioka, Chikashi and Kodera, Yasuhiro and Muto, Manabu and Wakai, Toshifumi and Yamazaki, Kentaro and Yasui, Wataru and Bando, Hideaki and Fujimoto, Yumi and Fukuoka, Shota and Harano, Kenichi and Kawazoe, Akihito and Kimura, Gen and Koganemaru, Shigehiro and Kogawa, Takahiro and Kotani, Daisuke and Kuboki, Yasutoshi and Matsumoto, Hiroshi and Matsumoto, Shingo and Mishima, Saori and Nakamura, Yoshiaki and Sawada, Kentaro and Shingaki, Sumito and Shitara, Kohei and Umemoto, Kumiko and Umemura, Shigeki and Yasuda, Kayo and Yoshino, Takayuki and Yamamoto, Noboru and Nishio, Kazuto and Japanese Soc Med Oncology and Japan Soc Clinical Oncology and Japanese Canc Assoc and Japan Society of Clinical Oncology and Japanese Society of Medical Oncology and Japanese Cancer Association
Cancer Science, ISSN 1347-9032, 09/2018, Volume 109, Issue 9, pp. 2980 - 2985
In Japan, the social (medical) health‐care system is on the way to being developed to advance personalized medicine through the implementation of cancer... 
gene panel testing | evidence level | guidance | next‐generation sequencing | solid cancer | next-generation sequencing | ONCOLOGY | COLLEGE | Care and treatment | Diagnosis | Translating and interpreting | Cancer | Research funding | Genes | Public speaking | Patients | Cancer therapies | Biopsy | Quality control | Children | Mutation | Drug therapy | Pharmaceuticals | Tumors | Report | Reports
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text WS1. the expansion of surgical indication in gastric colorectal cancer drug therapy
by Ishigami, H and Yamaguchi, H and Yamashita, H and Emoto, S and Kitayama, J and Yuki, S and Komatsu, Y and Nakatsumi, H and Kobayashi, Y and Takeuchi, S and Sogabe, S and Miyagishima, T and Kato, T and Hatanaka, K and Nakamura, M and Kudo, M and Akakura, N and Sonoda, N and Munakata, M and Sakata, Y and Akagi, Y and Beppu, T and Emi, Y and Kakechi, Y and Saeki, H and Oki, E and Fujita, F and Inomata, M and Sawai, T and Samura, H and Baba, H and Natsugoe, S and Ogata, Y and Tokunaga, S and Maehara, Y and Yoshida, Y and Hoshino, S and Miyake, T and Aisu, N and Tanimura, S and Yamashita, Y and Jang, J. E and Hyun, S. Y and Hwang, D. Y and Yoon, S. H and Kim, Y. D and Kim, S. J and Kim, J. S and Cheong, J.- W and Min, Y. H and Takamatsu, Y and Sunami, K and Miyamoto, T and Hata, H and Muta, T and Tsukada, J and Uozumi, K and Tamura, K and Chim, C. S and Ito, S and Mine, T and Sugawara, T and Fujishima, Y and Sasaki, R and Oyake, T and Murai, K and Ishida, Y and Ri, M and Iida, S and Okamoto, W and Okamoto, I and Arao, T and Nishina, S.- i and Ueda, S and Kawakami, H and Yanagihara, K and Kurata, T and Nishio, K and Nakagawa, K and Sukawa, Y and Yamamoto, H and Kunimoto, H and Nosho, K and Suzuki, H and Adachi, Y and Nobuoka, T and Kawayama, M and Mikami, M and Matsuno, T and Hasegawa, T and Hirata, K and Shinomura, Y and Sugimoto, N and Yoshinami, T and Yamamoto, S and Yagi, T and Imamura, F and Arita, S and Makiyama, A and Oda, H and ... and The Japanese and Korean Bendamustine Lymphoma Study Group
Annals of Oncology, ISSN 0923-7534, 10/2012, Volume 23, Issue suppl 11, pp. xi82 - xi98
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Impact of KRAS mutation on response and outcome of patients with stageIII non-squamous non-small cell lung cancer
by Yagishita, S and Horinouchi, H and Sunami, KS and Kanda, S and Fujiwara, Y and Nokihara, H and Yamamoto, N and Sumi, M and Shiraishi, K and Kohno, T and Furuta, K and Tsuta, K and Tamura, T and Ohe, Y
CANCER SCIENCE, ISSN 1347-9032, 10/2015, Volume 106, Issue 10, pp. 1402 - 1407
The frequency and clinical profile of patients with stageIII non-small cell lung cancer harboring KRAS mutations have not yet been well documented. Here, we... 
non-small cell lung cancer | ADJUVANT CHEMOTHERAPY | GROWTH-FACTOR-RECEPTOR | relapse | ADENOCARCINOMA | PHASE-III | chemoradiotherapy | CONCURRENT THORACIC RADIOTHERAPY | TRIAL | K-RAS MUTATIONS | THERAPY | CISPLATIN | ONCOLOGY | Biomarkers | KRAS
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text Monday, 27 August 2012
by Mendes-Ferreira, P and Maia-Rocha, C and Adao, R and Lourenco, A. P and Moura, C and Pinho, S and Areias, J. C and De Keulenaer, G. W and Leite-Moreira, A. F and Bras-Silva, C and Holzhauser, L and Lindner, D and Jenke, A and Schultheiss, H.- P and Westermann, D and Skurk, C and Misaka, T and Suzuki, S and Miyata, M and Kobayashi, A and Saitoh, S and Takeishi, Y and Czolbe, M and Pekarek, V and Williams, T and Panther, F and Strassen, J and Ritter, O and Voss, S and Nef, H. M and Szardien, S and Troidl, C and Kojonazarov, B and Visser, D and Hoffmann, J and Willmer, M and Hamm, C. W and Moellmann, H and Ljubojevic, S and Sedej, S and Sacherer, M and Leitinger, G and Kockskaemper, J and Pieske, B and Vorobyeva, N. M and Dobrovolsky, A. B and Titaeva, E. V and Kirienko, A. I and Panchenko, E. P and Nakamura, R and Matsue, Y and Mizukami, A and Ohno, M and Suzuki, M and Matsumura, A and Hashimoto, Y and Rosiak, M and Postula, M and Kaplon-Cieslicka, A and Trzepla, E and Czlonkowski, A and Filipiak, K. J and Opolski, G and Kosior, D. A and Andersson, T and Nagy, P and Niazi, M and Nylander, S and Wallentin, L and Mendell, J and Johnson, L and Ridout, G and He, L and Chen, S and Petrkova, M and Schneiderova, P and Kriegova, E and Kolar, Z and Taborsky, M and Petrek, M and Khuseyinova, N and Schnabel, R and Zeller, T and Gori, T and Schulz, A and Espinola-Klein, C and Lackner, K. J and Blankenberg, S and Muenzel, T. F and Wild, P. S and Amabile, N and Cheng, S and Larson, M. G and Ghorbani, A and Mc Cabe, E and Griffin, G and Cohen, K. S and Tedgui, A and Boulanger, C. M and Wang, T. J and ... and on behalf of BBC ONE investigators and on behalf of WHICH? Trial Investigators and on behalf of EPES Acute Cardiac Care group and on behalf of Interventional Genetic Study Group in Cardiovascular Disease's and on behalf of HPS2-THRIVE Collaborative Group and on behalf of Advantageous Predictors of Acute Coronary Syndrome Evaluation (APACE) and on behalf of The Milan and New-Tokyo Registry and on behalf of SAFETY Investigators and on behalf of Advance CRT Investigators and on behalf of the ARVA Investigators and on behalf of TIMI Study Group and on behalf of REFINE ICD Investigators and on behalf of RO-AHFS Study Investigators and on behalf of The PASCAL Investigators and on behalf of the KorHF investigators and on behalf of TECAM and on behalf of The INSIGHT (R)XT investigators and on behalf of ATA-AF investigators and on behalf of The ODIN Participants and on behalf of CREDO-Kyoto Registry Cohort-2 Investigators and on behalf of AHEAD investigators and on behalf of the RESET investigators and on behalf of ABSORB Cohort B and on behalf of RE-LY Trial Investigators and on behalf of the CORONA Study Group and on behalf of PROTECTOME and on behalf of CoLaus Study and on behalf of OFRECE Study and on behalf of BBK Registry and on behalf of FAST-MI 2010 and on behalf of ATOLL investigators and on behalf of HARVEST study group and on behalf of Royal Brompton Hospital NIHR Cardiovascular Biomedical Research Unit and on behalf of the PROSPER study group and on behalf of MAGGIC study group and on behalf of the DANPACE Investigators and on behalf of German Conn's Registry and on behalf of NANOPLASTY group and on behalf of j-Cypher Registry and on behalf of NIL-CHF Study Investigators and on behalf of the FAST-MI 2010 investigators and on behalf of Competence Network Heart Failure and on behalf of Gothia Cardiovascular and on behalf of OPTIMISE CRT Investigators and on behalf of EVEREST trial investigators and on behalf of The Tohoku Acute Heart Failure Registry and on behalf of investigators of the national registry of ACS, Portuguese Society of Cardiology and on behalf of BIOSOLVE-I Investigators and on behalf of Department of Cardiology, Second Hospital of Tianjin Medical University and on behalf of THALES Registry Investigators and on behalf of STICH Investigators and on behalf of Young @ Heart Investigators and on behalf of PROCARDIS Consortium and on behalf of PEGASO and on behalf of The SWEDEHEART group and on behalf of BWGIC (Belgian Working Group of Invasive Cardiology and on behalf of Med in NRW and For The Topp Registry Investigators and on behalf of PRISON and on behalf of ARISTOTLE investigators and on behalf of the RACE II investigators and on behalf of Euro Heart Survey PCI registry investigators and on behalf of the SPICE investigators and on behalf of The ISAR REACT 4 Investigators and on behalf of Yokohama Medical Center Clinical Research group and on behalf of DiaRegis-Study-Group and on behalf of The RHYTHM-AF Study Scientific Committee and on behalf of the Korea Acute Myocardial Infarction Registry and on behalf of AMIS Plus Investigators and on behalf of SYNTAX Investigators and on behalf of Advantage Predictors of Acute Coronary Syndrome Evaluation and on behalf of CREATE investigator group and on behalf of Follow Your Heart Project and on behalf of SYNTAX Trial Investigators and on behalf of WELCOME Study Investigators and on behalf of Arbeitsgemeinschaft Leitende Kardiologische Krankenhausarzte (ALKK) investigators and on behalf of investigators of the national registry of ACS, Portugese Society of Cardiology and on behalf of EVITA-HF (Evidence Based Treatment - Heart Failure) and on behalf of ESTROFA and on behalf of Second Department of Internal Medicine and on behalf of Korea Acute Myocardial Infarction Registry and on behalf of PRAGUE-2 and on behalf of German Diabetes and Dialysis Study Investigators and on behalf of Hull LifeLab and on behalf of on behalf of the DYDA Investigators and on behalf of OFICA study group and on behalf of BASKET-PROVE and on behalf of the Triple-Site versus Standard Resynchronization Therapy Study (TRUST CRT) Investigators and on behalf of Scripps Translational Science Institute and on behalf of OMEGA study group and on behalf of PL-ACS Invastigators and on behalf of German Aortic Valve Therapy Registry and on behalf of TO BELIEVERS and on behalf of PREDICTION Study Group and on behalf of The REACH registry investigators and on behalf of PL-ACS Investigators and on behalf of KNHI and on behalf of Emerging Concepts in Cardiovascular Medicine and on behalf of CHART-2 Investigators and on behalf of the Fushimi AF Registry investigators and on behalf of Brasilian Heart Study Group and on behalf of Taiwan acute coronary syndrome full spetrum registry study group
European Heart Journal, ISSN 0195-668X, 08/2012, Volume 33, Issue suppl 1, pp. 339 - 653
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Free and open source software and technology for sustainable development
by Sowe, Sulayman K and Parayil, Govindan, 1955 and Sunami, Atsushi, 1965
2012, ISBN 9280871862, xxvi, 346
Economic aspects | Information technology | Sustainable development | Economic development | Open source software
Book
Details down arrow
11. Full Text CD133 Expression at the Metastatic Site Predicts Patients’ Outcome in Colorectal Cancer with Synchronous Liver Metastasis
by Kishikawa, Junko and Kazama, Shinsuke and Oba, Koji and Hasegawa, Kiyoshi and Anzai, Hiroyuki and Harada, Yuzo and Abe, Hiroyuki and Matsusaka, Keisuke and Hongo, Kumiko and Oba, Masaru and Yasuda, Koji and Otani, Kensuke and Nishikawa, Takeshi and Tanaka, Toshiaki and Tanaka, Junichiro and Kiyomatsu, Tomomichi and Hata, Keisuke and Kawai, Kazushige and Nozawa, Hiroaki and Yamaguchi, Hironori and Ishihara, Soichiro and Sunami, Eiji and Ushiku, Tetsuo and Kitayama, Joji and Fukayama, Masashi and Kokudo, Norihiro and Watanabe, Toshiaki
Annals of Surgical Oncology, ISSN 1068-9265, 6/2016, Volume 23, Issue 6, pp. 1916 - 1923
CD133 is a transmembrane protein that is proposed to be a stem cell marker of colorectal cancer (CRC); however, the correlation between CD133 expression and... 
Oncology | Medicine & Public Health | Surgical Oncology | Surgery | SURGERY | STEM-CELLS | ONCOLOGY | PROGNOSIS | ALDH1 | CELL MARKERS CD133 | GROWTH | DIFFERENTIATION | IDENTIFICATION | CHEMOTHERAPY | CD44 | Colorectal Neoplasms - mortality | Neoplasms, Multiple Primary - mortality | Neoplasms, Multiple Primary - surgery | Colorectal Neoplasms - surgery | Neoplasms, Multiple Primary - metabolism | Prognosis | Follow-Up Studies | Neoplasm Recurrence, Local - metabolism | Humans | Liver Neoplasms - surgery | Neoplasms, Multiple Primary - secondary | Survival Rate | Liver Neoplasms - mortality | Neoplasm Recurrence, Local - mortality | Neoplasm Recurrence, Local - surgery | Neoplasm Recurrence, Local - pathology | AC133 Antigen - metabolism | Liver Neoplasms - metabolism | Biomarkers, Tumor - metabolism | Colorectal Neoplasms - pathology | Liver Neoplasms - secondary | Colorectal Neoplasms - metabolism | Medical research | Cancer patients | Patient outcomes | Colorectal cancer | Stem cells | Medicine, Experimental | Metastasis
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
12. Full Text S-1 plus oxaliplatin combined with radiation (SOX/RT) for preoperative locally advanced rectal carcinoma: final results of a phase II study (JACCRO CC-04: SHOGUN trial)
by Horie, H and Matsusaka, S and Ishihara, S and Kondo, K and Uehara, K and Oguchi, M and Murofushi, K and Ueno, M and Mizunuma, N and Shimbo, T and Kato, D and Okuda, J and Hashiguchi, Y and Nakazawa, M and Sunami, E and Kawai, K and Yamashita, H and Okada, T and Nakajima, T and Watanabe, T
Annals of Oncology, ISSN 0923-7534, 10/2016, Volume 27, Issue suppl_6
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
13. Full Text Trends of survival in patients with multiple myeloma in Japan: A multicenter retrospective collaborative study of the Japanese Society of Myeloma
by Ozaki, S and Handa, H and Saitoh, T and Murakami, H and Itagaki, M and Asaoku, H and Suzuki, K and Isoda, A and Matsumoto, M and Sawamura, M and Konishi, J and Sunami, K and Takezako, N and Hagiwara, S and Kuroda, Y and Chou, T and Nagura, E and Shimizu, K
Blood Cancer Journal, ISSN 2044-5385, 09/2015, Volume 5, Issue 9, pp. e349 - e349
ONCOLOGY | INTERNATIONAL STAGING SYSTEM | Japan - epidemiology | Multiple Myeloma - mortality | Humans | Middle Aged | Kaplan-Meier Estimate | Proportional Hazards Models | Hematopoietic Stem Cell Transplantation | Male | Antineoplastic Agents - therapeutic use | Multiple Myeloma - therapy | Aged, 80 and over | Adult | Female | Aged | Retrospective Studies | Letter to the Editor
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
14. Full Text Carfilzomib monotherapy in Japanese patients with relapsed or refractory multiple myeloma: A phase 1/2 study
by Iida, Shinsuke and Watanabe, Takashi and Matsumoto, Morio and Suzuki, Kenshi and Sunami, Kazutaka and Ishida, Tadao and Ando, Kiyoshi and Chou, Takaaki and Ozaki, Shuji and Taniwaki, Masafumi and Uike, Naokuni and Shibayama, Hirohiko and Hatake, Kiyohiko and Izutsu, Koji and Ishikawa, Takayuki and Shumiya, Yoshihisa and Tobinai, Kensei
Cancer Science, ISSN 1347-9032, 09/2019, Volume 110, Issue 9, pp. 2924 - 2932
This multicenter, open‐label phase 1/2 study evaluated single‐agent carfilzomib in 50 heavily pretreated Japanese patients with relapsed/refractory multiple... 
clinical trial | hematopoiesis | multiple myeloma | Japanese | carfilzomib | SURVIVAL | DEXAMETHASONE | ONCOLOGY | LENALIDOMIDE | OPEN-LABEL | Carfilzomib | Clinical trials | Relapse | Analysis | Multiple myeloma | Diseases | Leukopenia | Hematology | Neutrophils | FDA approval | Survival | Studies | Chemotherapy | Lymphopenia | Technical communication | Drug dosages | Neutropenia | Pharmaceuticals | Original
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
15. Full Text Pomalidomide alone or in combination with dexamethasone in Japanese patients with refractory or relapsed and refractory multiple myeloma
by Matsue, Kosei and Iwasaki, Hiromi and Chou, Takaaki and Tobinai, Kensei and Sunami, Kazutaka and Ogawa, Yoshiaki and Kurihara, Mari and Midorikawa, Shuichi and Zaki, Mohamed and Doerr, Thomas and Iida, Shinsuke
Cancer Science, ISSN 1347-9032, 11/2015, Volume 106, Issue 11, pp. 1561 - 1567
This phase 1, open‐label, dose‐escalation study investigated the tolerated dose (recommended dose), safety, efficacy, and pharmacokinetics of pomalidomide... 
dexamethasone | pharmacokinetics | Clinical trial | multiple myeloma | pomalidomide | Pomalidomide | Dexamethasone | Pharmacokinetics | Multiple myeloma | CELLS | ANALOGS | THALIDOMIDE | BORTEZOMIB | THERAPY | ONCOLOGY | LENALIDOMIDE | IMIDS | LOW-DOSE DEXAMETHASONE | Thalidomide - adverse effects | Dexamethasone - administration & dosage | Multiple Myeloma - mortality | Humans | Japan | Middle Aged | Salvage Therapy | Neoplasm Recurrence, Local - drug therapy | Male | Antineoplastic Agents - administration & dosage | Thalidomide - administration & dosage | Neoplasm Recurrence, Local - mortality | Thalidomide - pharmacokinetics | Disease-Free Survival | Thalidomide - analogs & derivatives | Asian Continental Ancestry Group | Maximum Tolerated Dose | Multiple Myeloma - drug therapy | Antineoplastic Agents - adverse effects | Female | Aged | Antineoplastic Agents - pharmacokinetics | Relapse | Diseases | Steroids | Medical research | Laboratories | Research funding | Studies | Lymphopenia | Medical prognosis | Stem cells | Bone marrow | Cytogenetics | Pharmaceutical industry | Drug dosages | Neutropenia | Original
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
16. Full Text Chloroquine potentiates the anti-cancer effect of 5-fluorouracil on colon cancer cells
by Sasaki, Kazuhito and Tsuno, Nelson H and Sunami, Eiji and Tsurita, Giichiro and Kawai, Kazushige and Okaji, Yurai and Nishikawa, Takeshi and Shuno, Yasutaka and Hongo, Kumiko and Hiyoshi, Masaya and Kaneko, Manabu and Kitayama, Joji and Takahashi, Koki and Nagawa, Hirokazu
BMC Cancer, ISSN 1471-2407, 07/2010, Volume 10, Issue 1, pp. 370 - 370
Background: Chloroquine (CQ), the worldwide used anti-malarial drug, has recently being focused as a potential anti-cancer agent as well as a chemosensitizer... 
APOPTOSIS | ARREST | INHIBITION | ONCOLOGY | GROWTH | LYMPHOMA | OLD DRUG | DEATH | AUTOPHAGY | INDUCTION | KINASES | Apoptosis - drug effects | Colonic Neoplasms - drug therapy | Humans | Antineoplastic Combined Chemotherapy Protocols | Chloroquine - therapeutic use | Antimalarials - therapeutic use | Autophagy | Blotting, Western | Immunoenzyme Techniques | Drug Synergism | Fluorouracil - therapeutic use | Antimetabolites, Antineoplastic - therapeutic use | Flow Cytometry | Cell Cycle | Colonic Neoplasms - pathology | Cell Line, Tumor | Cell Proliferation - drug effects | Colony-Forming Units Assay | Dosage and administration | Research | Drug therapy | Chloroquine | Colorectal cancer | Fluorouracil
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights